News | Proton Therapy | April 06, 2020

Varian Brings Machine Learning to Proton Treatment Planning

Eclipse v16 has received CE mark and is 510(k) pending

Eclipse v16 has received CE mark and is 510(k) pending

April 6, 2020 — Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technologies like machine learning, Varian announced the newest release of its treatment planning system, Eclipse v16. This new release includes intelligent features such as RapidPlan PT, the first clinical application of machine learning in proton treatment planning, and RT Peer Review, which is a collaborative workspace designed to streamline and accelerate the peer review process for radiotherapy treatment plans.   

Previously only available for photon-based radiotherapy treatment planning, RapidPlan is knowledge-based treatment planning software that enables clinicians to leverage knowledge and data from similar prior treatment plans to quickly develop high-quality personalized plans for patients.  This knowledge-based planning software is now available for proton treatment planning with RapidPlan PT.  The software also allows dose prediction with machine learning models that can be used as a decision support tool to determine which patients would be appropriate for proton or photon therapy. Varian is the first vendor in the industry to offer machine learning capability in both proton and photon treatment planning. 

"With the number of operational proton treatment rooms continuing to increase, there is a need for experienced proton therapy clinicians," said Kolleen Kennedy, chief growth officer, president, Proton Solutions, Varian. "RapidPlan PT helps bridge the learning curve, allowing established centers to share their models and clinical experience. The machine learning in RapidPlan PT has the potential to reduce proton treatment plan optimization from a one to eight hour process, as reported by clinical proton centers, to less than 10 minutes, while also potentially improving plan quality."

In many radiotherapy departments, radiation therapy peer review meetings have been routinely integrated into the clinical QA process for safer healthcare delivery for the patient.  Although the relevant patient information is manually retrievable from the clinical database, there is currently no efficient and effective platform to support these peer reviews.  The RT Peer Review feature in Eclipse v16 is designed for the oncology community to seamlessly integrate this review process into their normal clinical workflow by automatically presenting the necessary information that is required for peer review.

Eclipse v16 has received the CE mark and is 510(k) pending. For more information on Eclipse v16, visit www.varian.com/eclipse.

Related Content

For men with early-stage prostate cancer, choices about initial treatment carry varying risks of "financial toxicity," reports a study in The Journal of Urology, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Getty Images

News | Prostate Cancer | December 02, 2020
December 2, 2020 — ...
During active surveillance, prostate cancer is carefully monitored for signs of progression through regular prostate-specific antigen (PSA) screening, prostate exams, imaging, and repeat biopsies.

Getty Images

News | Prostate Cancer | November 18, 2020
November 18, 2020 — ...
Minimizing delays to treatment could improve cancer survival rates, say researchers

Getty Images

News | Radiation Oncology | November 10, 2020
November 10, 2020 — People whose treatment for cancer is delayed by even one month have in many cases a 6 to 13% high
In this retrospective cohort study of men with low-risk prostate cancer followed up for a median of 7.6 years, African American men, compared with non-Hispanic White men, had a statistically significant increased 10-year cumulative incidence of disease progression and definitive treatment, but not metastasis or prostate cancer–specific mortality

Getty Images

News | Prostate Cancer | November 04, 2020
November 4, 2020 — Previous studies have shown that African American men are 2.4 times as likely to die from...